Subchronic and chronic PCP treatment produces temporally distinct deficits in attentional set shifting and prepulse inhibition in rats

Psychopharmacology

Volumn 198, Issue 1, 2008, Pages 37-49

  Egerton, Alice ^a,b,c   Reid, Lee ^a   McGregor, Sandie ^a,b   Cochran, Susan M ^a,b,d   Morris, Brian J ^a   Pratt, Judith A ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b UNIVERSITY OF STRATHCLYDE   (United Kingdom)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

^d MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Attentional set shifting; Phencyclidine; Prefrontal cortex; Prepulse inhibition; Schizophrenia; Social interaction

Indexed keywords

AMPHETAMINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; PHENCYCLIDINE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATTENTION; CONTROLLED STUDY; LOCOMOTION; MALE; NEUROMODULATION; NONHUMAN; PREFRONTAL CORTEX; PREPULSE INHIBITION; PRIORITY JOURNAL; RAT; RECEPTOR BLOCKING; SCHIZOPHRENIA; SOCIAL INTERACTION;

AMPHETAMINE; ANIMALS; ATTENTION; BEHAVIOR, ANIMAL; CENTRAL NERVOUS SYSTEM STIMULANTS; COGNITION DISORDERS; DISCRIMINATION (PSYCHOLOGY); DOPAMINE; FRONTAL LOBE; HALLUCINOGENS; HYPERKINESIS; MALE; NEOSTRIATUM; PHENCYCLIDINE; RATS; RATS, LONG-EVANS; SCHIZOPHRENIC PSYCHOLOGY; SOCIAL BEHAVIOR; STARTLE REACTION;

EID: 43049083311     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00213-008-1071-5     Document Type: Article

References (109)

1. Adams B, Moghaddam B (1998) Corticolimbic dopamine neurotransmission is temporally dissociated from the cognitive and locomotor effects of phencyclidine. J Neurosci 18(14):5545-5554
2. Allen RM, Young SJ (1978) Phencyclidine-induced psychosis. Am J Psychiatry 135:1081-1084
3. Andreasen NC, Rezai K, Alliger R, Swayze VW, Flaum M, Kirchner P et al (1992) Hypofrontality in neuroleptic-naive patients and in patients with chronic schizophrenia. Assessment with xenon 133 single-photon emission computed tomography and the Tower of London. Arch Gen Psychiatry 49:943-958
4. Angrist B, Peselow E, Rubinstein M, Corwin J, Rotrosen J (1982) Partial improvement in negative schizophrenic symptoms after amphetamine. Psychopharmacology (Berl) 78(2):128-130
5. Beasley CL, Reynolds GP (1997) Parvalbumin-immunoreactive neurons are reduced in the prefrontal cortex of schizophrenics. Schizophr Res 24:349-355
6. Birrell JM, Brown VJ (2000) Medial frontal cortex mediates perceptual attentional set shifting in the rat. J Neurosci 20(11):4320-4324
7. Boulay D, Depoortere R, Louis C, Perrault G, Griebel G, Soubrie P (2004) SSR181507, a putative atypical antipsychotic with dopamine D2 antagonist and 5-HT1A agonist activities: improvement of social interaction deficits induced by phencyclidine in rats. Neuropharmacology 46(8):1121-1129
8. Braff D, Stone C, Callaway E, Geyer M, Glick I, Bali L (1978) Prestimulus effects on human startle reflex in normals and schizophrenics. Psychophysiology 15(4):339-343
9. Braff DL, Grillon C, Geyer MA (1992) Gating and habituation of the startle reflex in schizophrenic patients. Arch Gen Psychiatry. 49(3):206-215
10. Braff DL, Swerdlow NR, Geyer MA (1999) Symptom correlates of prepulse inhibition deficits in male schizophrenic patients. Am J Psychiatry 156(4):596-602
11. Breier A, Schreiber JL, Dyer J, Pickar D (1991) National Institute of Mental Health longitudinal study of chronic schizophrenia. Prognosis and predictors of outcome. Arch Gen Psychiatry 48:239-246
12. Breier A, Malhotra AK, Pinals DA, Weisenfeld NI, Pickar D (1997) Association of ketamine-induced psychosis with focal activation of the prefrontal cortex in healthy volunteers. Am J Psychiatry 154(6):805-811
13. BruinsSlot LA, Kleven MS, NewmanTancredi A (2005) Effects of novel antipsychotics with mixed D(2) antagonist/5-HT(1A) agonist properties on PCP-induced social interaction deficits in the rat. Neuropharmacology 49(7):996-1006
14. Buchanan RW, Breier A, Kirkpatrick B, Ball P, Carpenter WT Jr (1998) Positive and negative symptom response to clozapine in schizophrenic patients with and without the deficit syndrome. Am J Psychiatry 155(6):751-760
15. Buchsbaum MS, Nuechterlein KH, Haier RJ, Wu J, Sicotte N, Hazlett E et al (1990) Glucose metabolic rate in normals and schizophrenics during the Continuous Performance Test assessed by positron emission tomography. Br J Psychiatry 156:216-227
16. Buchsbaum MS, Haier RJ, Potkin SG, Nuechterlein K, Bracha HS, Katz M, Lohr J, Wu J, Lottenberg S, Jerabek PA et al (1992) Frontostriatal disorder of cerebral metabolism in never-medicated schizophrenics. Arch Gen Psychiatry 49(12):935-942
17. Buchsbaum MS, Hazlett EA (1998) Positron emission tomography studies of abnormal glucose metabolism in schizophrenia. Schizophr Bull 24:343-364
18. Carlsson A (1988) The current status of the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 1(3):179-186
19. Cochran SM, Fujimura M, Morris BJ, Pratt JA (2002) Acute and delayed effects of phencyclidine upon mRNA levels of markers of glutamatergic and GABAergic neurotransmitter function in the rat brain. Synapse 46(3):206-214
20. Cochran SM, Kennedy M, McKerchar CE, Steward LJ, Pratt JA, Morris BJ (2003) Induction of metabolic hypofunction and neurochemical deficits after chronic intermittent exposure to phencyclidine: differential modulation by antipsychotic drugs. Neuropsychopharmacology 28(2):265-275
21. Cochran SM, Egerton A, McGregor S, Morris BJ, Pratt JA (2006) Determination of neural circuitry associated with PCP-induced attentional set-shifting deficits in the rat. Western European CINP meeting, Belfast, N. Ireland, 2006
22. Cohen RM, Nordahl TE, Semple WE, Andreason P, Litman RE, Pickar D (1997) The brain metabolic patterns of clozapine- and fluphenazine-treated patients with schizophrenia during a continuous performance task. Arch Gen Psychiatry 54(5):481-486
23. Cosgrove J, Newell TG (1991) Recovery of neuropsychological functions during reduction in use of phencyclidine. J Clin Psychol 47(1):159-169
24. Danos P, Baumann B, Bernstein HG, Franz M, Stauch R, Northoff G et al (1998) Schizophrenia and anteroventral thalamic nucleus: selective decrease of parvalbumin-immunoreactive thalamocortical projection neurons. Psychiatry Res 82:1-10
25. David AS, Woodruff PW, Howard R, Mellers JD, Brammer M, Bullmore E et al (1996) Auditory hallucinations inhibit exogenous activation of auditory association cortex. Neuroreport 7:932-936
26. Deschenes A, Goulet S, Dore FY (2006) Rule shift under long-term PCP challenge in rats. Behav Brain Res 167(1):134-140
27. Deutch AY (1992) The regulation of subcortical dopamine systems by the prefrontal cortex: interactions of central dopamine systems and the pathogenesis of schizophrenia. J Neural Transm Suppl 36:61-89
28. Egerton A, Reid L, McKerchar CE, Morris BJ, Pratt JA (2005a) Impairment in perceptual attentional set-shifting following PCP administration: a rodent model of set-shifting deficits in schizophrenia. Psychopharmacology (Berl) 179(1):7784
29. Egerton A, Brett RR, Pratt JA (2005b) Acute delta9-tetrahydrocannabinol- induced deficits in reversal learning: neural correlates of affective inflexibility. Neuropsychopharmacology 30(10):1895-1905
30. Ellenbroek BA, Cools AR (2000) Animal models for the negative symptoms of schizophrenia. Behav Pharmacol 11(3-4):223-233
31. Elliott R, McKenna PJ, Robbins TW, Sahakian BJ (1995) Neuropsychological evidence for frontostriatal dysfunction in schizophrenia. Psychol Med 25(3):619-630
32. Fletcher PJ, Tenn CC, Rizos Z, Lovic V, Kapur S (2005) Sensitization to amphetamine, but not PCP, impairs attentional set shifting: reversal by a D1 receptor agonist injected into the medial prefrontal cortex. Psychopharmacology (Berl) 183(2):190-200
33. Gao X-M, Shirakawa O, Du F, Tamminga CA (1993) Delayed regional metabolic actions of phencyclidine. Eur J Pharmacol 241:7-15
34. Geyer MA, Krebs-Thomson K, Braff DL, Swerdlow NR (2001) Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review. Psychopharmacology (Berl) 156(2-3):117-154
35. Goldberg TE, Kelsoe JR, Weinberger DR, Pliskin NH, Kirwin PD, Berman KF (1988) Performance of schizophrenic patients on putative neuropsychological tests of frontal lobe function. Int J Neurosci 42:51-58
36. Goldberg TE, Weinberger DR (1996) Effects of neuroleptic medications on the cognition of patients with schizophrenia: A review of recent studies. J Clin Psychiatry 57:62-65
37. Grace AA (1993) Cortical regulation of subcortical dopamine systems and its possible relevance to schizophrenia. J Neural Transm Gen Sect 91:111-134
38. Greenberg BD, Segal DS (1985) Acute and chronic behavioral interactions between phencyclidine (PCP) and amphetamine: evidence for a dopaminergic role in some PCP-induced behaviors. Pharmacol Biochem Behav 23(1):99-105
39. Harvey PD, Howanitz E, Parrella M, White L, Davidson M, Mohs RC, Hoblyn J, Davis KL (1998) Symptoms, cognitive functioning, and adaptive skills in geriatric patients with lifelong schizophrenia: a comparison across treatment sites. Am J Psychiatry 155:1080-1086
40. Harvey PD, Keefe RSE (2001) Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment. Am J Psychiatry 158:176-184
41. Haut MW, Cahill J, Cutlip WD, Stevenson JM, Makela EH, Bloomfield SM (1996) On the nature of Wisconsin Card Sorting Test performance in schizophrenia. Psychiatry Res 65(1):15-22
42. Hazlett EA, Buchsbaum MS, Jeu LA, Nenadic I, Fleischman MB, Shihabuddin L et al (2000) Hypofrontality in unmedicated schizophrenia patients studied with PET during performance of a serial verbal learning task. Schizophr Res 43:33-46
43. Heresco-Levy U (2003) Glutamatergic neurotransmission modulation and the mechanisms of antipsychotic atypicality. Prog Neuropsychopharmacol Biol Psychiatry 27(7):1113-1123
44. Hertzmann M, Reba RC, Kotlyarov EV (1990) Single photon emission computed tomography in phencyclidine and related drug abuse. Am J Psychiatry 147(2):255-256
45. Jaskiw GE, Karoum FK, Weinberger DR (1990) Persistent elevations in dopamine and its metabolites in the nucleus accumbens after mild subchronic stress in rats with ibotenic acid lesions of the medial prefrontal cortex. Brain Res 534:321-323
46. Javitt DC (1987) Negative schizophrenic symptomatology and the PCP (phencyclidine) model of schizophrenia. Hillside J Clin Psychiatry 9(1):12-35
47. Javitt DC, Zukin SR (1991) Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 148:1301-1308
48. Jentsch JD, Tran A, Le D, Youngren KD, Roth RH (1997a) Subchronic phencyclidine administration reduces mesoprefrontal dopamine utilization and impairs prefrontal cortical-dependent cognition in the rat. Neuropsychopharmacology 17(2):92-99
49. Jentsch JD, Redmond DE Jr, Elsworth JD, Taylor JR, Youngren KD, Roth RH (1997b) Enduring cognitive deficits and cortical dopamine dysfunction in monkeys after long-term administration of phencyclidine. Science 277(5328):953-955
50. Jentsch JD, Taylor JR, Roth RH (1998) Subchronic phencyclidine administration increases mesolimbic dopaminergic system responsivity and augments stress- and psychostimulant-induced hyperlocomotion. Neuropsychopharmacology 19(2):105-113
51. Jentsch JD, Roth RH (1999) The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 20:201-25
52. Johnson KM, Phillips M, Wang C, Kevetter GA (1998) Chronic phencyclidine induces behavioral sensitization and apoptotic cell death in the olfactory and piriform cortex. J Neurosci Res 52(6):709-722
53. Joyce E, Hutton S, Mutsatsa S, Gibbins H, Webb E, Paul S, Robbins T, Barnes T (2002) Executive dysfunction in first-episode schizophrenia and relationship to duration of untreated psychosis: the West London Study. Br J Psychiatry 181(Suppl):s38-44
54. Kelly PH, Iversen SD (1976) Selective 6OHDA-induced destruction of mesolimbic dopamine neurons: abolition of psychostimulant-induced locomotor activity in rats. Eur J Pharmacol 40(1):45-56
55. Krystal JH, Karper LP, Seibyl JP, Freeman GK, Delaney R, Bremner JD et al (1994) Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry 51:199-214
56. Laruelle M (2000) The role of endogenous sensitization in the pathophysiology of schizophrenia: implications from recent brain imaging studies. Brain Res Brain Res Rev 31(2-3):371-384
57. Laruelle M, Abi-Dargham A, Casanova MF, Toti R, Weinberger DR, Kleinman JE (1993) Selective abnormalities of prefrontal serotonergic receptors in schizophrenia. A postmortem study. Arch Gen Psychiatry 50(10):810-818
58. Laurent V, Podhorna J (2004) Subchronic phencyclidine treatment impairs performance of C57BL/6 mice in the attentional set-shifting task. Behav Pharmacol 15(2):141-148
59. Lee PR, Brady DL, Shapiro RA, Dorsa DM, Koenig JI (2005) Social interaction deficits caused by chronic phencyclidine administration are reversed by oxytocin. Neuropsychopharmacology 30(10):1883-1894
60. Luby ED, Cohen CB, Rosenbaum G, Gottlieb JS, Kelly R (1959) Study of a new schizophrenomimetic drugFSerynl. Arch Neurol Psychiatry 81:363-369
61. Malhotra AK, Pinals DA, Weingartner H, Sirocco K, Missar CD, Pickar D, Breier A (1996) NMDA receptor function and human cognition: the effects of ketamine in healthy volunteers. Neuropsychopharmacology 14(5):301-307
62. Meyer-Lindenberg A, Miletich RS, Kohn PD, Esposito G, Carson RE, Quarantelli M, Weinberger DR, Berman KF (2002) Reduced prefrontal activity predicts exaggerated striatal dopaminergic function in schizophrenia. Nat Neurosci 5(3):267-271
63. Mishara AL, Goldberg TE (2004) A meta-analysis and critical review of the effects of conventional neuroleptic treatment on cognition in schizophrenia: opening a closed book. Biol Psychiatry 55(10):1013-1022
64. Morgan CJ, Monaghan L, Curran HV (2004) Beyond the K-hole: a 3-year longitudinal investigation of the cognitive and subjective effects of ketamine in recreational users who have substantially reduced their use of the drug. Addiction 99(11):1450-1461
65. Mortimer AM (1997) Cognitive function in schizophrenia-do neuroleptics make a difference? Pharmacol Biochem Behav 56:789-795
66. Morris BJ, Cochran SM, Pratt JA (2005) PCP: from pharmacology to modelling schizophrenia. Curr Opin Pharmacol 5(1):101-106
67. Nudmamud S, Reynolds LM, Reynolds GP (2003) N-acetylaspartate and N-Acetylaspartylglutamate deficits in superior temporal cortex in schizophrenia and bipolar disorder: a postmortem study. Biol Psychiatry 53(12):1138-1141
68. Olney JW, Labrugere J, Price MT (1989) Pathological changes induced in cerebrocortical neurons by phancydictive and related drugs. Science 244:1360-1362
69. Owen AM, Roberts AC, Polkey CE, Sahakian BJ, Robbins TW (1991) Extra-dimensional versus intra-dimensional set shifting performance following frontal lobe excisions, temporal lobe excisions or amygdalo-hippocampectomy in man. Neuropsychologia 29(10):993-1006
70. Pantelis C, Barber FZ, Barnes TR, Nelson HE, Owen AM, Robbins TW (1999) Comparison of set-shifting ability in patients with chronic schizophrenia and frontal lobe damage. Schizophr Res 37(3):251-270
71. Perry W, Braff DL (1994) Information-processing deficits and thought disorder in schizophrenia. Am J Psychiatry 151(3):363-367
72. Perry W, Geyer MA, Braff DL (1999) Sensorimotor gating and thought disturbance measured in close temporal proximity in schizophrenic patients. Arch Gen Psychiatry 56(3):277-281
73. Piercey MF, Ray CA (1988) Dramatic limbic and cortical effects mediated by high affinity PCP receptors. Life Sci 43(4):379-385
74. Potkin SG, Buchsbaum MS, Jin Y, Tang C, Telford J, Friedman G et al (1994) Clozapine effects on glucose metabolic rate in striatum and frontal cortex. J Clin Psychiatry 55(Suppl B):63-66
75. Pouzet B, Didriksen M, Arnt J (2002a) Effects of the 5-HT(7) receptor antagonist SB258741 in animal models for schizophrenia. Pharmacol Biochem Behav 71(4):655-665
76. Pouzet B, Didriksen M, Arnt J (2002b) Effects of the 5-HT(6) receptor antagonist, SB271046, in animal models for schizophrenia. Pharmacol Biochem Behav 71(4):635-643
77. Reynolds LM, Cochran SM, Morris BJ, Pratt JA, Reynolds GP (2005) Chronic phencyclidine administration induces schizophrenia-like changes in Nacetylaspartate and N-acetylaspartylglutamate in rat brain. Schizophr Res 73(23):147-152
78. Rodefer JS, Murphy ER, Baxter MG (2005) PDE10A inhibition reverses subchronic PCP-induced deficits in attentional set shifting in rats. Eur J Neurosci 21(4):1070-1076
79. Rowland L, Bustillo JR, Lauriello J (2001) Proton magnetic resonance spectroscopy (H-MRS) studies of schizophrenia. Semin Clin Neuropsychiatry 6(2):121-130
80. Sams-Dodd F (1995a) Automation of the social interaction test by a video-tracking system: behavioral effects of repeated phencyclidine treatment. J Neurosci Methods 59:157-167
81. Sams-Dodd F (1995b) Distinct effects of d-amphetamine and phencyclidine on the social behavior of rats. Behav Pharmacol 6:55-65
82. Sams-Dodd F (1996) Phencyclidine-induced stereotyped behavior and social isolation in rats: a possible animal model of schizophrenia. Behav Pharmacol 7:3-23
83. Sams-Dodd F (1997) Effect of novel antipsychotic drugs on phencyclidine-induced stereotyped behavior and social isolation in the rat social interaction test. Behav Pharmacol 8:196-215
84. Sams-Dodd F (1998a) Effects of continuous D-amphetamine and phencyclidine administration on social behavior, stereotyped behavior, and locomotor activity in rats. Neuropsychopharmacology 19:18-25
85. Sams-Dodd F (1998b) Effects of diazepam, citalopram, methadone and naloxone on PCP-induced stereotyped behavior and social isolation in the rat social interaction test. Neurosci Biobehav Rev 23:287-293
86. Sams-Dodd F (1998c) Effects of dopamine agonists and antagonists on PCP-induced stereotyped behavior and social isolation in the rat social interaction test. Psychopharmacology (Berl) 135:182-193
87. Sams-Dodd F (1998d) A test of the predictive validity of animal models of schizophrenia based on phencyclidine and D-amphetamine. Neuropsychopharmacology 18:293-304
88. Sams-Dodd F (1999) Phencyclidine in the social interaction test: an animal model of schizophrenia with face and predictive validity. Rev Neurosci 10:59-90
89. Sams-Dodd F (2004) (+) MK-801 and phencyclidine induced neurotoxicity do not cause enduring behaviors resembling the positive and negative symptoms of schizophrenia in the rat. Basic Clin Pharmacol Toxicol 95(5):241-246
90. Schultz SK, Andreasen N (1999) Schizophrenia. The Lancet 353:1425-1430
91. Schroeder J, Buchsbaum MS, Siegel BV, Geider FJ, Haier RJ, Lohr J et al (1994) Patterns of cortical activity in schizophrenia. Psychol Med 24:947-955
92. Schroeder J, Buchsbaum MS, Siegel BV, Geider FJ, Lohr J, Tang C et al (1996) Cerebral metabolic activity correlates of subsyndromes in chronic schizophrenia. Schizophr Res 19:41-53
93. Spielewoy C, Markou A (2003) Withdrawal from chronic phencyclidine treatment induces long lasting depression in brain reward function. Neuropsychopharmacology 28(6):1106-1116
94. Steinpresis RE (1996) The behavioral and neurochemical effects of phenyclidine in humans and animals: some implications for modeling psychosis. Behav Brain Res 74(1-2):45-55
95. Steward LJ, Kennedy MD, Morris BJ, Pratt JA (2004) The atypical antipsychotic drug clozapine enhances chronic PCP-induced regulation of prefrontal cortex 5HT2A receptors. Neuropharmacology 47(4):527-537
96. Swerdlow NR, Geyer MA, Braff DL (2001) Neural circuit regulation of prepulse inhibition of startle in the rat: current knowledge and future challenges. Psychopharmacology (Berl) 156(2-3):194-215
97. Sullivan EV, Shear PK, Zipursky RB, Sagar HJ, Pfefferbaum A (1994) A deficit profile of executive, memory, and motor functions in schizophrenia. Biol Psychiatry 36:641-653
98. Tamminga CA, Tanimoto K, Kuo S, Chase TN, Contreras PC, Rice KC, Jackson AE, O'Donohue TL (1987) PCP-induced alterations in cerebral glucose utilization in rat brain: blockade by metaphit, a PCP-receptor-acylating agent. Synapse 1(5):497-504
99. Tamminga CA, Thaker GK, Buchanan R, Kirkpatrick B, Alphs LD, Chase TN et al (1992) Limbic system abnormalities identified in schizophrenia using positron emission tomography with fluorodeoxyglucose and neocortical alterations with deficit syndrome. Arch Gen Psychiatry 49:522-530
100. Tanaka K, Suzuki M, Sumiyoshi T, Murata M, Tsunoda M, Kurachi M (2003) Subchronic phencyclidine administration alters central vasopressin receptor binding and social interaction in the rat. Brain Res 992(2):239-245
101. Tenn CC, Kapur S, Fletcher PJ (2005) Sensitization to amphetamine, but not phencyclidine, disrupts prepulse inhibition and latent inhibition. Psychopharmacology (Berl) 180(2):366-376
102. van Kammen DP, Boronow JJ (1988) Dextro-amphetamine diminishes negative symptoms in schizophrenia. Int Clin Psychopharmacol 3(2):111-121
103. Vollenweider FX, Leenders KL, Scharfetter C, Antonini A, Maguire P, Missimer J, Angst J (1997) Metabolic hyperfrontality and psychopathology in the ketamine model of psychosis using positron emission tomography (PET) and [18F]fluorodeoxyglucose (FDG). Eur Neuropsychopharmacol 7(1):9-24
104. Volz HP, Gaser C, Hager F, Rzanny R, Mentzel HJ, Kreitschmann-Andermahr I, Kaiser WA, Sauer H (1997) Brain activation during cognitive stimulation with the Wisconsin Card Sorting Test-a functional MRI study on healthy volunteers and schizophrenics. Psychiatry Res 75(3):145-157
105. Volz H, Gaser C, Hager F, Rzanny R, Ponisch J, Mentzel H et al (1999) Decreased frontal activation in schizophrenics during stimulation with the continuous performance test: a functional magnetic resonance imaging study. Eur Psychiat 14:17-24
106. Weinberger DR, Berman KF, Suddath R, Torrey EF (1992) Evidence of dysfunction of a prefrontal-limbic network in schizophrenia: a magnetic resonance imaging and regional cerebral blood flow study of discordant monozygotic twins. Am J Psychiatry 149(7):890-897
107. Weissman AD, Dam M, London ED (1987) Alterations in local cerebral glucose utilization induced by phencyclidine. Brain Res 435(1-2):29-40
108. Wolkin A, Sanfilipo M, Wolf AP, Angrist B, Brodie JD, Rotrosen J (1992) Negative symptoms and hypofrontality in chronic schizophrenia. Arch Gen Psychiatry 49:959-965
109. Woodruff PW, Wright IC, Bullmore ET, Brammer M, Howard RJ, Williams SC et al (1997) Auditory hallucinations and the temporal cortical response to speech in schizophrenia: a functional magnetic resonance imaging study. Am J Psychiatry 154:1676-1682